These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29283559)

  • 41. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of interleukin-11 on the hematopoietic action of granulocyte colony-stimulating factor.
    Momose K; Taguchi K; Saitoh M; Yasuda S; Miyata K
    Arzneimittelforschung; 2002; 52(11):857-61. PubMed ID: 12489258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mobilization of peripheral blood progenitor cells by Betafectin PGG-Glucan alone and in combination with granulocyte colony-stimulating factor.
    Patchen ML; Liang J; Vaudrain T; Martin T; Melican D; Zhong S; Stewart M; Quesenberry PJ
    Stem Cells; 1998; 16(3):208-17. PubMed ID: 9617896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
    Copelan E; Pohlman B; Rybicki L; Kalaycio M; Sobecks R; Andresen S; Dean R; Koo A; Chan J; Sweetenham J; Bolwell B
    Bone Marrow Transplant; 2009 Jan; 43(2):101-5. PubMed ID: 18794865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum granulocyte colony-stimulating factor (G-CSF) and interleukin-1 (IL-1) concentrations after chemotherapy-induced neutropenia in normal and tumor-bearing dogs.
    Bravo L; Legendre AM; Hahn KA; Rohrbach BW; Abraha T; Lothrop CD
    Exp Hematol; 1996 Jan; 24(1):11-7. PubMed ID: 8536786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.
    Wang H; Liu Y; Li ZY; Fan X; Hemminki A; Lieber A
    Blood; 2010 Jan; 115(3):592-600. PubMed ID: 19965652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.
    Mittal A; Schulze K; Ebensen T; Weissmann S; Hansen S; Guzmán CA; Lehr CM
    J Control Release; 2015 May; 206():140-52. PubMed ID: 25795506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-inflammatory effects of granulocyte colony-stimulating factor.
    Hartung T
    Curr Opin Hematol; 1998 May; 5(3):221-5. PubMed ID: 9664164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surgical wound healing using hemostatic gauze scaffold loaded with nanoparticles containing sustained-release granulocyte colony-stimulating factor.
    Yuan W; Liu Z
    Int J Nanomedicine; 2011; 6():3139-49. PubMed ID: 22163165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
    Vijenthira A; Maganti M; Kukreti V; Kuruvilla J; Tiedemann R; Chen C; Crump M; Prica A
    Leuk Lymphoma; 2019 Oct; 60(10):2576-2579. PubMed ID: 30997853
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of mitomycin-C and etoposide in cell culture and in nude mice: the role of G-CSF mutein.
    Fujii M; Ohnuma T; Szrajer L; Holland JF; Biller H; Okabe M
    Cancer Invest; 1993; 11(3):283-90. PubMed ID: 7683568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma.
    Blosser N; Jupp J; Yau P; Stewart D
    Clin Pharmacokinet; 2020 Jan; 59(1):7-23. PubMed ID: 31385204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Curative treatments of murine Colon26 solid tumors by immunochemotherapy with G-CSF and OK-432.
    Kudo C; Saito M; Yoshida T
    Immunopharmacology; 1995 Apr; 29(3):235-43. PubMed ID: 7542645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel G-CSF conjugated anionic globular dendrimer: Preparation and biological activity assessment.
    Mousavi Motlagh SS; Seyedhamzeh M; Ahangari Cohan R; Shafiee Ardestani M; Vaziri B; Azadmanesh K; Saberi S; Masoumi V
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00826. PubMed ID: 34269522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 20 years of rituximab treatment: what have we learnt?
    Renner C
    Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunomodulators and fungal infections: use of antifungal drugs in combination with G-CSF.
    Yamamoto Y; Uchida K; Klein TW; Friedman H; Yamaguchi H
    Adv Exp Med Biol; 1992; 319():231-41. PubMed ID: 1384280
    [No Abstract]   [Full Text] [Related]  

  • 60. Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
    Rubenstein JL
    Leuk Lymphoma; 2019 Feb; 60(2):281-283. PubMed ID: 30188237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.